نتایج جستجو برای: recombinant tissue plasminogen activator rtpa

تعداد نتایج: 1042975  

2017
Karl Boyle Raed A. Joundi Richard I. Aviv

Long standing, evidence based approved therapies for acute ischemic stroke include intravenous thrombolysis therapy (IVT) with alteplase (recombinant tissue plasminogen activator, rtPA) given within 4.5 h; aspirin therapy within 48 h; management in an acute stroke unit and hemicraniectomy in cases of malignant infarction. Multiple recent positive randomized controlled trials (RCTs) have now als...

Alia Saberi, Amirreza Ghayegran, Hamidreza Hatamian, Mojtaba Abbasalizade, Parisa Shahshahani, Samaneh Ghorbani Shirkouhi, Sasan Andalib, Zeinab Ehtiatkar,

Background: Thrombolytic therapy is the recommended treatment of acute ischemic stroke. It is crucial to evaluate the treatment results with recombinant Tissue Plasminogen Activator (r-TPA) in patients with acute stroke. Objectives: This study aimed to evaluate treatment outcomes with r-TPA in patients with acute stroke in a referral stroke center in Iran. Materials & Methods: In this retrosp...

Journal: :Arteriosclerosis, thrombosis, and vascular biology 1998
O Gurevitz A Goldfarb H Hod M Feldman B Shenkman D Varon M Eldar A Inbal

Platelet adhesion to exposed subendothelium is mediated by platelet receptor glycoprotein Ib and polymeric von Willebrand factor (vWF). To improve the results of coronary arterial thrombolysis, fragments of vWF with enhanced glycoprotein Ib binding competitive with native vWF have been proposed as adjuvants to recombinant tissue-type plasminogen activator (rtPA). We designed a recombinant vWF f...

Journal: :Hong Kong medical journal = Xianggang yi xue za zhi 2010
A Y L Lau Y O Y Soo C A Graham W K Woo E H C Wong H Leung A Y Y Chan L W C Au V H L Ip C S F Leung V Hui W C Shum J Abrigo D Y W Siu S C H Yu L K S Wong T W Leung

OBJECTIVES To assess time management of stroke thrombolysis triage and functional outcomes in patients receiving recombinant tissue plasminogen activator for hyperacute stroke, and identify bottlenecks in delivery of the treatment. DESIGN Prospective study. SETTING A university teaching hospital in Hong Kong. PATIENTS Patients with suspected hyperacute stroke referred to the stroke thromb...

2016
Daniel Amitrano Ivan Rocha Ferreira da Silva Janaina Oliveira Osvaldo J. M. Nascimento

Stroke is one of the leading causes of morbidity and mortality worldwide, and since the approval of intravenous thrombolysis (IVT) with recombinant tissue plasminogen activator (rtPA, alteplase) in 19961 as a treatment option, acute stroke management has experienced a paradigm shift. Focus has moved to prompt and accurate diagnosis followed by time-sensitive administration of a therapy that eff...

Journal: :Hong Kong medical journal = Xianggang yi xue za zhi 2012
Michael Tang

The stroke team in Hong Kong only performs duty during office hours due to limited resources,1 but 57% of strokes occur during non-office hours (from Queen Elizabeth Hospital [QEH]; data unpublished). Queen Elizabeth Hospital, the only hospital with 24-hour stroke service, treats roughly 1800 patients a year (QEH; data unpublished). Since there are approximately 18 000 stroke patients annually,...

Journal: :Journal of the American College of Cardiology 2016
Priyank Khandelwal Dileep R Yavagal Ralph L Sacco

Acute ischemic stroke (AIS) is the leading cause of disability worldwide and among the leading causes of mortality. Although intravenous tissue plasminogen activator (IV-rtPA) was approved nearly 2 decades ago for treatment of AIS, only a minority of patients receive it due to a narrow time window for administration and several contraindications to its use. Endovascular approaches to recanaliza...

Journal: :Stroke 2009
Kazunori Toyoda Masatoshi Koga Masaki Naganuma Yoshiaki Shiokawa Jyoji Nakagawara Eisuke Furui Kazumi Kimura Hiroshi Yamagami Yasushi Okada Yasuhiro Hasegawa Kazuomi Kario Satoshi Okuda Kazutoshi Nishiyama Kazuo Minematsu

BACKGROUND AND PURPOSE A retrospective, multicenter, observational study was conducted to document clinical outcomes and to identify outcome predictors in patients treated with low-dose intravenous recombinant tissue plasminogen activator (0.6 mg/kg alteplase), which was approved in Japan in 2005, within 3 hours of stroke onset. METHODS Consecutive patients with stroke treated with recombinan...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید